Hemorrhagic Complications

  • Cynthia M. Thaik
  • Patrick O’Gara
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)


Over the past decade there has been a marked increase in the use of thrombolytic, anticoagulant, and antiplatelet agents in a wide variety of clinical settings, including the prophylaxis and treatment of deep venous thrombosis (DVT) and pulmonary emboli (PE), the prevention of embolic strokes in arrial fibrillation (AF), and the management of acute myocardial infarction (MI). In very high-risk patients, the incidence of calf vein thrombosis may range from 40% to 80%, proximal vein thrombosis from 10% to 20%, and clinical PE from 4% to 10%


Atrial Fibrillation Acute Myocardial Infarction International Normalize Ratio Unstable Angina Major Bleeding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salzman EW, Hirsh J. Prevencion of venous thromboembolism. In Coleman RW, Hirsh J, Marder VJ, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia: JB Lippincott, 1994:1332.Google Scholar
  2. 2.
    Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 155:469, 1995.PubMedGoogle Scholar
  3. 3.
    Heart and Stroke Facts, American Heart Association, 1996.Google Scholar
  4. 4.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1:349, 1988.Google Scholar
  5. 5.
    Brodie BR, Grines CL, Ivanhoe R, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the primary angioplasty registry. Circulation 90:156, 1994.PubMedGoogle Scholar
  6. 6.
    Guerrci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 317:1613, 1987.Google Scholar
  7. 7.
    European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 301:797, 1979.Google Scholar
  8. 8.
    Gruppo Italiano per lo Studo della Sopravvivenza nell’ Infarto Miocardico. (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 2:871, 1987.Google Scholar
  9. 9.
    The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction. N Engl J Med 314:465, 1986.Google Scholar
  10. 10.
    Collen D, Topol CJ, Tefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized placebo-controlled trial. Circulation 70:1012, 1984.PubMedGoogle Scholar
  11. 11.
    Verstraete M, Brower RW, Witten D, et al. Double blind randomized trial of intravenous tissue-type plasminogen activator: A prospective, randomized placebo-controlled trial. Lancet 2:965, 1985.PubMedGoogle Scholar
  12. 12.
    Wilcox RG, Olsson CG, Skene AM, et al. Anglo-Scandinavian study of early thrombolysis (ASSET): Trial of tissue plasminogen activator for mortality-reduction in acute myocardial infarction. Lancet 2:525, 1985.Google Scholar
  13. 13.
    The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase 1 findings. N Engl J Med 312:932, 1985.Google Scholar
  14. 14.
    TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction (TIMI) phase II trial. N Engl J Med 320:618, 1990.Google Scholar
  15. 15.
    Roberts R, Rogers WJ, Meuller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction; results of the thrombolysis in myocardial infarction (TIMI II-B study). Circulation 83:422, 1991.PubMedGoogle Scholar
  16. 16.
    Gruppo Italiano per lo Studo della Soprawivenza nell’ Infarto Miocardico. GISSI-2. A factorial randomized trial of anistreplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336:65, 1990.Google Scholar
  17. 17.
    AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study. Lancet 335:427, 1990.Google Scholar
  18. 18.
    The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336:71, 1990.Google Scholar
  19. 19.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 329:673, 1992.Google Scholar
  20. 20.
    Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In Colman RW, Hirsh J, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994:1.Google Scholar
  21. 21.
    Stump D, Collen D. The fibrinolytic system: Implications for thrombolytic therapy. In Califf R, Mark D, Wagner G (eds). Acute Coronary Care in the Thrombolytic Era. St. Louis, MO: Yearbook Medical, 1988:58.Google Scholar
  22. 22.
    Majerus PW, Broze GJ, Miletich JP, et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In Hardman JG, Limbird LE (eds). Goodman & Gilman’s The Pharmacological Basic of Therapeutics. New York: McGraw Hill, 1996:1341.Google Scholar
  23. 23.
    Cannon CP, McCabe CH, Gibson M, et al. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997, in press.Google Scholar
  24. 24.
    Bode C, Kohler B, Smalling RW, et al. Reteplase (r-PA): A novel recombinant plasminogen activator. Fibrinolysis 9(Suppl. 1):97, 1995.Google Scholar
  25. 25.
    Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 92:2044, 1995.PubMedGoogle Scholar
  26. 26.
    Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In Coleman RW, Hirsh J, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994:1584.Google Scholar
  27. 27.
    Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low-molecular weight heparins and heparin. Blood 59:1239, 1982.PubMedGoogle Scholar
  28. 28.
    Harker LA. Antiplateler and Anticoagulant therapy. In Handin RI, Lux SE, Stossel TP (eds). Blood: Principles and Practice of Hematology. Philadelphia: JB Lippincott, 1995.Google Scholar
  29. 29.
    Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40:498, 1990.PubMedGoogle Scholar
  30. 30.
    Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522, 1994.PubMedGoogle Scholar
  31. 31.
    Hirsh J. Optimal intensity and monitoring warfarin. Am J Cardiol 1995:39B.Google Scholar
  32. 32.
    Moran N, Fitzgerald GA. Mechanism of action of antiplatelet drugs. In Coleman RW, Hirsh J, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994:1623.Google Scholar
  33. 33.
    FitzGerald GA. Dipyridamole. N Engl J Med 316:1247, 1987.PubMedGoogle Scholar
  34. 34.
    Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in platelet dependent disease states. Drugs 34:222, 1987.PubMedGoogle Scholar
  35. 35.
    Califf RM, Fortin DF, Tenaglia AN, Sane DC. Clinical risks of thrombolytic therapy. Am J Cardiol 69:12A, 1992.PubMedGoogle Scholar
  36. 36.
    The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673, 1993.Google Scholar
  37. 37.
    Leblanc R, Haddad G, Robitaille Y. Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis. Neurosurgery 31:586, 1992.PubMedGoogle Scholar
  38. 38.
    Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 115:256, 1991.PubMedGoogle Scholar
  39. 39.
    Selker HP, Beshansky JR, Schmid CH, et al. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) project results. Circulation 90:1657, 1994.PubMedGoogle Scholar
  40. 40.
    Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during rhrombolytic therapy. Lancet 342:1523, 1993.PubMedGoogle Scholar
  41. 41.
    TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 260:2849, 1988.Google Scholar
  42. 42.
    SWIFT (Should We Intervene Following Thrombolysis?) Trial Group. SWIFT trial of delayed elective intervention vs. consecutive treatment after thrombolysis with anistreplase in acute myocardial infarction. Br Med J 302:555, 1991.Google Scholar
  43. 43.
    Boks AL, Brommer EJ, Schaim SW, et al. Hemostasis and fibrinolysis in severe liver failure and their relationship to hemorrhage. Hepatology 6:79, 1986.PubMedGoogle Scholar
  44. 44.
    Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In Lane DA, Lindahl U (eds). Heparin: Chemical and Biological Properties Clinical Applications. London: Edward Arnold, 1989:517.Google Scholar
  45. 45.
    Yett HS, Skillman JJ, Salzman EW. The hazards of heparin plus aspirin. N Engl J Med 298:1092, 1978.PubMedGoogle Scholar
  46. 46.
    Jick H, Slone D, Borda IT, et al. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 279:284, 1968.PubMedGoogle Scholar
  47. 47.
    Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 187:144, 1989.Google Scholar
  48. 48.
    Van Der Meer FJ, Rosendaal FR, Van Den Broucke JP, et al. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med 153:1557, 1993.PubMedGoogle Scholar
  49. 49.
    Isaacs C, Paltiel O, Blake G, et al. Age-associated risks of prophylactic anti-coagulation in the setting or hip fracture. Am J Med 96:487, 1994.PubMedGoogle Scholar
  50. 50.
    Fihn SD, McDonnell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 118:511, 1993.PubMedGoogle Scholar
  51. 51.
    Beyth RJ, Landefeld CS. Anticoagulants in older patients. A safety perspective. Drug Aging 6:45, 1995.Google Scholar
  52. 52.
    Hylek EM, Singer DE. Risk factors for intracranial hermorrhage in outpatients taking warfarin. Ann Intern Med 120:897, 1994.PubMedGoogle Scholar
  53. 53.
    Tracy RP, Bovill EG. Fibrinolytic parameters and hemostatic monitoring: Identifying and predicting patients at risk for major hemorrhagic events. Am J Cardiol 69:52A, 1992.PubMedGoogle Scholar
  54. 54.
    Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1, 1988.PubMedGoogle Scholar
  55. 55.
    Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 85:353, 1988.PubMedGoogle Scholar
  56. 56.
    Mueller HS, Rao AK, Forman SA. Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 10:479, 1987.PubMedGoogle Scholar
  57. 57.
    Sane DC, Califf RM, Topol EJ, et al. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med 111:1010, 1989.PubMedGoogle Scholar
  58. 58.
    McGill JB, Schneider DJ, Arfken Cl, et al. Factors tesponsible tor impaired fibrinolysis in obsese subjects and NIDDM patients. Diabetes 43:104, 1994.PubMedGoogle Scholar
  59. 59.
    Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study. Ann Intern Med 103:837, 1985.PubMedGoogle Scholar
  60. 60.
    Collen D, Bounameaux H, De Cock F, et al. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 73:511, 1986.PubMedGoogle Scholar
  61. 61.
    Urokinase Pulmonary Embolism Trial Study Group. Urokinase pulmonary embolism trial: Phase 1 results. JAMA 214:2163, 1970.Google Scholar
  62. 62.
    Urokinase Pulmonary Embolism Trial Study Group. Urokinase/streptokinase embolism trial: Phase 2 trials results. JAMA 229:1606, 1974.Google Scholar
  63. 63.
    Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction — results from the GUSTO-I trial. Circulation 93:870, 1996.PubMedGoogle Scholar
  64. 61.
    Shapiro Ga, Huntzinger SW, Wilson JE. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol 67:477, 1977.PubMedGoogle Scholar
  65. 65.
    Vacek JL, Kazuhira H, Rosamond TL, et al. Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines. Am J Cardiol 68:557, 1991.PubMedGoogle Scholar
  66. 66.
    Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: A coronary care unit experience. Am Heart J 128:719, 1994.PubMedGoogle Scholar
  67. 67.
    Kelton J, Warkentin T. Heparin-induced thrombocytopenia. In Coller BS (ed). Progress in Hemostasis and Thrombosis, Vol. 10. Philadelphia: W.B. Saunders, 1991:1.Google Scholar
  68. 68.
    Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332:1314, 1995.Google Scholar
  69. 69.
    Harrington RA, Sane DC, Califf RM, et al. Clinical importance of thrombocytopenia occurring in hospital phase after administration of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 23:891, 1994.PubMedGoogle Scholar
  70. 70.
    Bauer KA, Weitz JI. Laboratory matkers of coagulation and fibrinolysis. In Coleman RW, Hirsh J, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994:1197.Google Scholar
  71. 71.
    Kaplan KL. Laboratory markers of platelet activation. In Coleman RW, Hirsh J, et al. (eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994:1180.Google Scholar
  72. 72.
    Sloan MA, Gore JM. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol 69:21A, 1992.PubMedGoogle Scholar
  73. 73.
    Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 83:448, 1992.Google Scholar
  74. 74.
    Levine MN, Goldhaber SZ, Gore JM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 108:291S, 1995.Google Scholar
  75. 75.
    GUSTO IIA investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631, 1994.Google Scholar
  76. 76.
    Antman EM. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624, 1994.PubMedGoogle Scholar
  77. 77.
    Antman EM for the TIMI 9B investigators. Hirudin in acute myocardial infarction: Final results of the Thrombolysis and Thrombin Inhibition in Myocardial Infarction. (TIMI) 9B Trial. Circulation 94:911, 1996.Google Scholar
  78. 79.
    Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinanc plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94:891, 1996.PubMedGoogle Scholar
  79. 80.
    Goldhaber SZ, Buring JE, Lipnick RJ, et al. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep vein thrombosis. Am J Med 76:393, 1984.PubMedGoogle Scholar
  80. 81.
    Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 108:276S, 1995.Google Scholar
  81. 82.
    Fernandez F, Nguyen P, van Ryn J, et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43:491, 1986.PubMedGoogle Scholar
  82. 83.
    Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate, and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 556:245, 1989.PubMedGoogle Scholar
  83. 84.
    Raschke RA, Reilly BM, Gguidry J, et al. The weight-based heparin nomogram compared with a “standard card” nomogram: A randomized controlled trial. Ann Intern Med 119:874, 1993.PubMedGoogle Scholar
  84. 85.
    Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154:49, 1994.PubMedGoogle Scholar
  85. 86.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina? N Engl J Med 319:1105, 1988.PubMedGoogle Scholar
  86. 87.
    Serneri GGN, Roveli F, Gensini GF, et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1:937, 1987.Google Scholar
  87. 88.
    The SCATI Group. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 2:182, 1989.Google Scholar
  88. 89.
    Bleich SD, Nichols T, Schumacher R, et al. The role of heparin following coronary thrombolysis with tissue plasminogen activator. Circulation 80(Suppl. 1):113, 1989.Google Scholar
  89. 90.
    Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79:281, 1989.PubMedGoogle Scholar
  90. 91.
    Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433, 1990.PubMedGoogle Scholar
  91. 92.
    Collins R, Scrimgeour A, Yusuf S, et al. Reduction of fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 318:1162, 1988.PubMedGoogle Scholar
  92. 93.
    Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 108:312S, 1995.Google Scholar
  93. 94.
    Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 26:313, 1995.PubMedGoogle Scholar
  94. 95.
    Nesvold A, Kontny F, Abildgaard, et al. Safety of high doses of low molecular weight heparin (fragmin) in acute myocardial infarction. A dose-finding study. Thromb Res 64:579, 1991.PubMedGoogle Scholar
  95. 96.
    Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 347:561, 1996.Google Scholar
  96. 97.
    Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease — The Fragmin In Unstable Coronary Artery Disease study (FRIC). Circulation, 1997, in press.Google Scholar
  97. 98.
    Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Lenn E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 69:157, 1993.PubMedGoogle Scholar
  98. 99.
    Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardr G, Buller H, Hoet B, Bichler J, Close P, on behalf of the European Hirudin in Thrombosis Group. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 22:1080, 1993.PubMedGoogle Scholar
  99. 100.
    Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 83:1510, 1991.PubMedGoogle Scholar
  100. 101.
    Lidon R, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina: Anticoagulant, antithrombotic and clinical ettects. Circulation 88:1495, 1993.PubMedGoogle Scholar
  101. 102.
    Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S, Daum R, Palmeri S, Sequeira R, Sharma G, et al. for the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: Results of the TIMI 7 trial (abstr). J Am Coll Cardiol 23:56, 1994.Google Scholar
  102. 103.
    Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21:1039, 1993.PubMedGoogle Scholar
  103. 104.
    Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trail. Circulation 89:1557, 1994.PubMedGoogle Scholar
  104. 105.
    Lidon RM, Theroux P, Bonan R, et al. A pilot early angiographie patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567, 1994.PubMedGoogle Scholar
  105. 106.
    Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction (TIMI 5) trial. J Am Coll Cardiol 23:993, 1994.PubMedGoogle Scholar
  106. 107.
    Neuhaus KL, Niederer W, Wagner J, et al. HIT (Hirudin for the Improvement of Thrombolysis): Results of a dose escalation study (abstr). Circulation 88:1292, 1993.Google Scholar
  107. 108.
    Neuhaus KL, Essen RV, Tebber U, et al. Safety observations from the pilot phase of the randomized rhirudin for improvement of thrombolysis (HIT III) study. Circulation 90:1638, 1994.PubMedGoogle Scholar
  108. 109.
    The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775, 1996.Google Scholar
  109. 110.
    Cannon CP, Maraganore JM, Loscalzo J. Anticoagu effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 71:778, 1993.PubMedGoogle Scholar
  110. 111.
    Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic stable coronary disease: Safety, half life and effect on coagulation parameters. Circulation 88:2015, 1993.PubMedGoogle Scholar
  111. 112.
    Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622, 1993.PubMedGoogle Scholar
  112. 113.
    van den Bos AA, Deckers JW, Heyndricks GR, et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88:2058, 1993.PubMedGoogle Scholar
  113. 114.
    Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. HEVETICA Investigators. N Engl J Med 333:757, 1995.PubMedGoogle Scholar
  114. 115.
    Bittl JA on behalf of the Hirulog Angioplasty Study Investigators. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. Am Heart J 130:658, 1995.PubMedGoogle Scholar
  115. 116.
    Ginsberrg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90:2385, 1994.Google Scholar
  116. 117.
    Eriksson BI, Kalebo P, Ekman S, et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 72:227, 1994.PubMedGoogle Scholar
  117. 118.
    Eriksson BI, Kalebo P, Ekman S, et al. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393 (abstr). Circulation 90:1569, 1994.Google Scholar
  118. 119.
    Ginsberrg JS, Nurmohamed MT, Gent M, et al. Effects on thrombin generation of single injections of hirulog in patients with calf vein thrombosis. Thromb Haemost 72:523, 1994.Google Scholar
  119. 120.
    Parest F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW023): An open pilot study. Thromb Haemost 70:386, 1993.Google Scholar
  120. 121.
    Douketis JD, Turpie AGG. Combined antiplatelet-anticoagulant therapy: Rationale and safety considerations. In Ezekowitz MD (ed). Long-Term Antithrombotic Antiplatelet Therapy in the Post-infarct Patient. American Journal of Cardiology Continuing Education Series. 1994:16.Google Scholar
  121. 122.
    Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 307:1676, 1982.PubMedGoogle Scholar
  122. 123.
    Turpie AGG, Hirsh J, Gunstensen J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1:1242, 1988.PubMedGoogle Scholar
  123. 124.
    Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 329:524, 1993.PubMedGoogle Scholar
  124. 125.
    Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 101:427, 1991.PubMedGoogle Scholar
  125. 126.
    Altman R, Rouvier J, Gurfinkel E, et al. Comparison of high dose with low dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 94:2113, 1996.PubMedGoogle Scholar
  126. 127.
    Acar J, Iung B, Boissel JP, et al. AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94:2107, 1996.PubMedGoogle Scholar
  127. 128.
    The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 323:1505, 1990.Google Scholar
  128. 129.
    Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 84:527, 1991.Google Scholar
  129. 130.
    Peterson P, Boysan G, Godtfredsen J, et al. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1:175, 1989.Google Scholar
  130. 131.
    Ezekowitz MD, Bridgers SI, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 327:1406, 1992.PubMedGoogle Scholar
  131. 132.
    Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation study. J Am Coll Cardiol 18:349, 1991.PubMedGoogle Scholar
  132. 133.
    Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687, 1994.Google Scholar
  133. 134.
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449, 1994.Google Scholar
  134. 135.
    The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156:409, 1996.Google Scholar
  135. 136.
    Amman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 101:427, 1991.Google Scholar
  136. 137.
    Saour JN, Sieck JO, Marno LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 322:428, 1990.PubMedGoogle Scholar
  137. 138.
    Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2:989, 1980.Google Scholar
  138. 139.
    Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323:147, 1990.PubMedGoogle Scholar
  139. 140.
    ASPECT Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343:499, 1994.Google Scholar
  140. 141.
    Olsson JE, Brechter C, Backlund H, et al. Anticoagulant us antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 11:4, 1980.PubMedGoogle Scholar
  141. 142.
    Baker RN. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease: Report of the Veterans Administration Cooperative study of atherosclerosis. Neurology 11:132, 1961.Google Scholar
  142. 143.
    Hill AB, Marshall J, Shaw DA. Cerebrovascular disease: Trial of long term anticoagulant therapy in cerebrovascular disease. QJ Med 29:597, 1960.Google Scholar
  143. 144.
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129, 1989.Google Scholar
  144. 145.
    Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 296:313, 1988.Google Scholar
  145. 146.
    The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 338:1345, 1991.Google Scholar
  146. 147.
    Sze PC, Reitman D, Pincus MM, et al. Antiplatelet agents in the secondary prevention of stroke: Meta-analysis of the randomized control trials. Stroke 19:436, 1988.PubMedGoogle Scholar
  147. 148.
    Goldstein LB, Bonito AJ, Matchar CB, et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Carotid endarterectomy. Stroke 27:801, 1996.Google Scholar
  148. 149.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81, 1994.Google Scholar
  149. 150.
    Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 75:23B, 1995.PubMedGoogle Scholar
  150. 151.
    Prichard PJ, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J 298:493, 1989.Google Scholar
  151. 152.
    Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501, 1989.PubMedGoogle Scholar
  152. 153.
    Uchiyama S, Sone R, Nagayama T, et al. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 20:1643, 1989.PubMedGoogle Scholar
  153. 154.
    Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 82:17, 1990.PubMedGoogle Scholar
  154. 155.
    Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084, 1996.PubMedGoogle Scholar
  155. 156.
    Tcheng J, Ellis SG, George BS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation 90;1757, 1994.PubMedGoogle Scholar
  156. 157.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956, 1994.Google Scholar
  157. 158.
    Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa Integrin in patients undergoing percutaneous coronary intervention. Circulation 91:2882, 1995.PubMedGoogle Scholar
  158. 159.
    Lincoff AM, Tcheng JE, Bass TA, et al. A multicenter, randomized, double blind pilot trial of standard versus low dose weight adjusted heparin in patients treated with the platelet GPIIb/IIa receptor antibody c7E3 during percutaneous coronary angioplasty (abstr). J Am Coll Cardiol 25:80A, 1995.Google Scholar
  159. 160.
    Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 7B(Suppl. 3A):35, 1996.Google Scholar
  160. 161.
    Ferguson JJ. Meeting highlights: ACC 45th annual scientific session. Circulation 94:1, 1996.PubMedGoogle Scholar
  161. 162.
    Tcheng JE, Harrington RA, Kandice KM, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein, IIb/IIIa blocker, Integrelin in elective coronary intervention. Circulation 91:2151, 1995.PubMedGoogle Scholar
  162. 163.
    Blankenship J, Mandak J, Aguirre F, et al. Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial (abstr). J Am Coll Cardiol 27:360, 1996.Google Scholar
  163. 164.
    Kleinman NS, Ohman ME, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: Results of the TAMI 8 pilot study. J Am Coll Cardiol 22:381, 1993.Google Scholar
  164. 165.
    Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Randomized, double-blind, placebo-controlled doseranging study of tirofiban (MK-383) platelet IIb/ IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996:536.Google Scholar
  165. 165.
    Adam HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 94:1167, 1996.Google Scholar
  166. 166.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581, 1995.Google Scholar
  167. 167.
    Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346:1509, 1995.Google Scholar
  168. 168.
    Hommel M, Boissel JP, Cornu C, et al. Termination of trial of streptokinase in severe acute ischaemic stroke [letter]. Lancet 345:57, 1994.Google Scholar
  169. 169.
    Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet 345:578, 1995.PubMedGoogle Scholar
  170. 170.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017, 1995.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Cynthia M. Thaik
  • Patrick O’Gara

There are no affiliations available

Personalised recommendations